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Sudden Death During Follow-up After New-onset
Ventricular Tachycardia’s in Vascular Surgery Patients
Tamara Winkel1, Olaf Schouten2, Michiel T. Voute1,
Sanne E. Hoeks1, Mirko de Melis3, Hence J. Verhagen1,
Don Poldermans1. 1Erasmus Medical Center, Rotterdam,
Netherlands; 2Reinier de Graaf Hospital, Delft, Nether-
lands; 3Medtronic BRC BV, Maastricht, Netherlands
Objectives: Vascular surgery patients are at increased
risk for late sudden cardiac death. Identification of patients
at risk during surgery offers the opportunity for focused
therapy.
Methods: We monitored 483 vascular surgery pa-
tients, without a history of cardiac arrhythmias, to identify
perioperative new-onset ventricular tachyarrhythmia’s
(VT) using a continuous electrocardiographic device for 72
hours. Preoperative cardiac risk factors, left ventricular
function, medical therapy, inflammation status, and periop-
erative ischemia were noted in all.
Results: New-onset perioperative VT, defined as sus-
tained VT, was detected in 33 (7%) patients. Patients with
perioperative VT had a significantly worse left ventricular
function (p  0.04), were undertreated with statins (p 
0.02), however their inflammation status did not differ (p
0.18). Patients with VT had a higher incidence of myocar-
dial ischemia, compared to patients without VT (30% vs
18%, p  0.10). VT was preceded by ischemia in 74%.
During a median follow-up of 2.0 years (IQR 1.1-3.1),
cardiac death occurred in 56 patients, in 48 (86%) classified
as sudden death. In patients with VT 27% died; 78% were
due to sudden cardiac death. After adjusting for risk factors,
new-onset perioperative VT was associated with sudden
cardiac death (HR 2.3; 95% CI 1.2-5.7, figure).
Conclusions: Late sudden cardiac death is associated
with perioperative VT. Cardiac high-risk patients with peri-
operative VT might constitute a population that could
benefit from preemptive ICD implantation, on top of op-
timal medical therapy.
Author Disclosures: M. de Melis: Medtronic BCRMaas-
tricht, Employment (full or part-time); S. E. Hoeks: Noth-
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Combined Endovascular and Surgical Treatment of
Severe (TASC D) Aortoiliac Occlusive Disease
Vikram S. Kashyap, Turki Albacker. Vascular Surgery,
Cleveland Clinic, Cleveland, OH
Background: Aortobifemoral bypass grafting has been
the traditional treatment for extensive aorto-iliac occlusive
disease (AIOD). We present a case of recanalization, percuta-
neous transluminal angioplasty and stenting (R/PTAS) of the
iliac vessels combined with femoral endarterectomy in a pa-
tient with severe AIOD. We have performed nearly 100 of
these procedureswith goodmid-term resolutionof symptoms
and durability. Concomitant treatment of femoral disease
often needed. R/PTAS is a suitable, lessinvasive alternative to
aortic reconstruction for treatment of patients with severe
AIOD.
Technical Description: A 63-year-old male business-
man had debilitating claudication at 20-30 m. He had a
complicated recovery from recent cardiac surgery with a
prolonged hospitalization. His other co-morbidities in-
cluded diabetes, emphysema, and100 pack year smoking
history. Preoperative studies revealed absent R-sided
pulses, dampened PVR waveforms and CTA showing ex-
tensive bilateral iliac disease (TASC D). The operative
sequence was angiography, R iliac recanalization, R femoral
endarterectomy and patching, stenting of both iliacs and
then patch closure. The key technical components include
long-segment arterial recanalization, aortic re-entry, and
intervention via the patch prior to completion. The patient
had resolution of symptoms, palpable femoral arteries, and
normalization of PVR waveforms.
Author Disclosures: T. Albacker: Nothing to disclose;
V. S. Kashyap: Nothing to disclose.
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Preoperative Beta-Blocker Utilization
Brian Nolan1, Jens Eldrup-Jorgensen3, Adam Beck1, An-
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Objectives:To determine if a regional quality improve-
ment effort can increase preoperative beta-blocker (BB)
usage and decrease postoperative MI (POMI) rate.
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implemented in 2003 at 11 centers participating in the
Vascular Study Group of New England (VS GNE). A 90%
target was set and feedback given at bi-annual meetings. BB
usage ( 1-mo preoperative (P) vs chronic (C)) and POMI
rates were prospectively collected among patients undergo-
ing open AAA repair (n 926) and lower extremity bypass
(n 2123) from 2003 through 2008. Predictors of POMI
were determined using multivariate logistic regression.
Rates of BB utilization and POMI were analyzed over time
across strata of patient risk based on a multivariate model.
Results: Overall BB utilization was 86% (AAA 90%,
LEB 84%, p  0.001), and in-hospital POMI occurred in
5.5% of patients (AAA 7.6%, LEB 4.6%, p  0.001). P-BB
usage increased in low risk and C- BB usage increased in
medium/high risk pts, but POMI rates did not change over
time (table). Age 70 (OR 2.1), positive stress test (OR
2.2), CHF (OR 1.7), C-BB (OR 1.7), resting heart rate
(HR) 70 (OR 1.8) and diabetes (OR 1.6) were indepen-
dent predictors of POMI. Resting HR was 67, 70, 70 for
patients on C-BB, P-BB and no BB.
Conclusions: Despite regional improvement in BB us-
age, POMI rate did not decrease, perhaps due to P-BB doses
that did not changeHR.Anegative impact ofC-BBonPOMI
was unexpected and requires further investigation.
Author Disclosures: A. Beck: Nothing to disclose; J. L.
Cronenwett: Nothing to disclose; J. Eldrup-Jorgensen:
Nothing to disclose; P. P. Goodney: Nothing to disclose;
D. Likosky: Nothing to disclose; B. Nolan: Nothing to
disclose; A. Schanzer: Nothing to disclose; A. Stanley:
Nothing to disclose.
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Peripherally Inserted Central Catheter (PICC) Usage
Patterns and Associated Upper Extremity Venous
Thrombosis
Timothy K. Liem, Keenan E. Yanit, Shannon E. Moseley,
Claudia A. Rumwell, Gregory J. Landry, Erica Mitchell,
Gregory Moneta. Vascular Surgery, Oregon Health & Sci-
ence University, Portland, OR
Objectives: PICC line placement may be complicated
by superficial (SVT) or deep vein thrombosis (DVT). The
purpose of this study was to determine if any PICC line
characteristics were associated with venous thrombotic
complications.
Methods: All upper extremity venous duplex scans
over a 12-month period were reviewed, selecting pa-
tients with isolated SVT or DVT, and recently placed
PICC lines ( 30 days). Patient characteristics, PICC
insertion sites, and technical specifications were evalu-ated. Over the same period, PICC usage patterns were
determined from an electronic medical record query.
Results: Over the 12-month period, 690 patients un-
derwent upper extremity venous duplex scans, revealing
219 isolated SVTs and 154 DVTs. Concurrently, 685
PICC line procedures were reviewed (74% basilic, 16%
brachial vein, 10% cephalic). 44 of 219 (20%) isolated SVTs
were associated with a PICC line (32% cephalic, 68% ba-
silic). 54 of 154 DVTs (35%) were associated with a PICC
line. Basilic vein PICCs accounted for 45 DVTs (83%) and
brachial vein PICCs for 9 (7.5%), but there were no DVTs
associated with cephalic vein PICC lines. (p  0.03)
Conclusions: PICC lines placed in the cephalic vein are
associated with isolated SVT, while those placed in the
basilic vein are more frequently associated with SVT and
DVT. The cephalic vein should be preferentially utilized for
PICC line placement to minimize the risk for iatrogenic
DVT formation.
Author Disclosures: G. J. Landry: Nothing to disclose;
T. K. Liem: Nothing to disclose; E. Mitchell: Nothing to
disclose; G. Moneta: Nothing to disclose; S. E. Moseley:
Nothing to disclose; C. A. Rumwell: Nothing to disclose;
K. E. Yanit: Nothing to disclose.
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ative Experience of Trainees and Practicing Vascular
Surgeons
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Center, Tucson, AZ; 8VA Medical Center, Washington,
DC; 9Washington Hospital Center, Washington, DC;
10University of Wisconsin, Madison, WI
Objectives: We aimed to find out whether the scope
and complexity of current vascular surgery training reflect
contemporary vascular surgery practice.
Methods: We analyzed the operative logs submitted to
the VS B-ABS by recent vascular surgery residents applying
for the qualifying exam (QE) (2006-2009) or by practicing
vascular surgeons applying for the recertifying exam (RE)
(2003-2009). Regional variations in operative data for
applicants to the REwere also examined. An analysis of case
volume and performance on the written exam was per-
formed.
Results: The reported operative experience of QE ap-
plicants exceeds or equals the operative experience of RE
